Custom cover image
Custom cover image

Nanomedicines : design, delivery and detection / edited by Martin Braddock,AstraZeneca Research and Development, Macclesfield, UK

Contributor(s): Resource type: Ressourcentyp: Buch (Online)Book (Online)Language: English Series: RSC e-book collection | RSC drug discovery series ; 51Publisher: Cambridge : Royal Society of Chemistry, [2016]Description: 1 Online-Ressource (354 pages)ISBN:
  • 9781849739474
  • 9781782622536
  • 9781782627517
Subject(s): Additional physical formats: 9781849739474 | Erscheint auch als: Nanomedicines Druck-Ausgabe.LOC classification:
  • R857.N34
DOI: DOI: 10.1039/9781782622536Online resources: Summary: Nanomedicines and nanopharmacology is a rapidly developing and evolving field with new techniques and applications under constant development. This book will provide an overview of the chemistry of nanocarrier design and the considerations that need to be made when developing a nanomedicine. Providing an understanding of the relationship of nanocarrier, drug and targetting moieties and physico-chemical properties, this title will provide an accurate and current representation of the field by addressing the promises, prospects and pitfalls of nanomedicine. Covering a wide range of areas in detail, this book will provide an excellent companion for medicinal chemists, pharmacologists and biochemists working in industry or academiaSummary: 4.2 External Magnetic Device4.3 Labeling Mesenchymal Stem Cells with Supraparamagnetic Iron Oxide; 4.4 Adhesion of m-MSCs to the Tissue Injured Site; 4.5 Animal Studies; 4.6 Conclusion; Acknowledgments; References; 5.1 Introduction; 5.2 Theranostic Carrier Materials; 5.3 Theranostics and Imaging; 5.4 Conclusions; References; 6.1 Introduction; 6.2 Imaging for In vivo Evaluation of the Spatio-temporal Distribution Characteristics of Nanomedicines; 6.3 Use of Imaging to Understand and Optimize Nanomedicine Performance; 6.4 Clinical Experience and Future Considerations; ReferencesSummary: 7.1 Introduction7.2 Anticancer Agents Incorporating Micelles under Clinical Evaluation; 7.3 Verification of the EPR Effect using Imaging Mass Spectrometry; 7.4 Discussion and Conclusion; References; 8.1 Introduction; 8.2 Topoisomerase 1 Inhibitors; 8.3 Hypoxia Inducible Factor-1 Inhibitors; 8.4 Cancer Stem Cells; 8.5 Combination Therapy; 8.6 CRLX101; 8.7 Conclusion; References; 9.1 Introduction; 9.2 Nanocarriers for Drug Delivery to Solid Tumors; 9.3 Doxil®-The First FDA-approved Nano-drug; 9.4 Taxane-based Nanodelivery (Abraxane® and Genexol-PM®); 9.5 CrEL-free Formulations of PTXSummary: Cover; Contents; Preface; Chapter 1 Design Considerations for Properties of Nanocarriers on Disposition and Efficiency of Drug and Gene Delivery; Chapter 2 Targeting Cyclins and Cyclin-dependent Kinases Involved in Cell Cycle Regulation by RNAi as a Potential Cancer Therapy; Chapter 3 Nanoparticle Carriers to Overcome Biological Barriers to siRNA Delivery; Chapter 4 Magnetic Targeting as a Vehicle for the Delivery of Nanomedicines; Chapter 5 The Development of Theranostics -- Imaging Considerations and Targeted Drug DeliverySummary: Chapter 6 The Role of Imaging in Nanomedicine Development and Clinical TranslationChapter 7 Anticancer Agent-Incorporating Polymeric Micelles: from Bench to Bedside; Chapter 8 Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101; Chapter 9 Nanodelivery Strategies in Breast Cancer Chemotherapy; Chapter 10 Developing a Predictable Regulatory Path for Nanomedicines by Accurate and Objective Particle Measurement; Chapter 11 Nanomedicine: Promises and Challenges; Chapter 12 The Challenge of Regulating Nanomedicine: Key IssuesSummary: Chapter 13 Doxil® -- the First FDA-approved Nano-drug: from Basics via CMC, Cell Culture and Animal Studies to Clinical UseSubject Index; References; 1.1 Introduction; 1.2 Types of Nanocarriers/Nanoparticles; 1.3 Physicochemical Factors that Affect Nanoparticle Efficiency; 1.4 Conclusions; References; 2.1 Introduction; 2.2 The Cell Cycle; 2.3 Deregulation of the Cell Cycle in Cancer; 2.4 RNA Interference; 2.5 Concluding Remarks; Acknowledgments; References; 3.1 Introduction; 3.2 Extracellular Barriers; 3.3 Cellular Barriers; 3.4 siRNA Delivery Systems; References; 4.1 IntroductionPPN: PPN: 857777483Package identifier: Produktsigel: ZDB-1-RSEK
No physical items for this record
KIT – The University in the Helmholtz Association                         Home | Impressum | Datenschutz | Barrierefreiheit | KIT